长春瑞滨联合顺铂方案作为乳腺癌术后辅助化疗的安全性观察  

A Clinical Study on the Safety of Vinorelbine Combined with Cisplatin in the Treatment of the Postoperative Adjuvant Chemotherapy in Breast Cancer

作　　者：高莉莉[1] 黄新恩[1] 唐金海[2] 蔡炜宇[1] 江伟[1] 束永前[3] 

机构地区：[1]江苏省肿瘤医院化疗科 [2]江苏省肿瘤医院普外科,江苏南京210009 [3]江苏省人民医院肿瘤科,江苏南京210000

出　　处：《肿瘤基础与临床》2008年第2期127-128,共2页journal of basic and clinical oncology

基　　金：2005年江苏省人事厅"六大人才高峰"项目;江苏省科技发展计划项目(编号:BS2006006);2007年江苏省卫生厅"333高层次人才培养工程"项目

摘　　要：目的评价长春瑞滨联合顺铂(NP方案)用作乳腺癌术后辅助化疗的安全性。方法20例乳腺癌,给予NVB+DPP,NVB 40mg/m2,i.v gtt d1,8,DDP 20 mg/m2,i.v gtt d1-5,21 d为1周期,给药后监测毒副反应。结果患者的主要毒副反应表现为骨髓抑制、胃肠道反应,均为可逆性。结论长春瑞滨联合顺铂方案作为乳腺癌术后辅助化疗毒副作用可耐受,值得进一步观察疗效。Objective To investigate the safety of combination of vinorelbine and cisplatin as an adjuvant chemotherapy for breast cancer. Methods 20 breast cancer patients were treated with NVB 40 mg/m^2 i. v on day 1 and days 8, cisplatin 20 mg/m^2 i. v from day 1 to day 5, and repeated every 21 days. Toxicity was evaluated after each cycle of chemotherapy. Results Main side effects were neutropenia and gastrointestinal syndrome. Conclusions The vinorelbine combined with cisplatin is safe, and feasible, and the toxicity is tolerable and preventable： This regimen is warranted to be further investigated.

关 键 词：长春瑞滨 顺铂 乳腺癌 术后辅助化疗 安全性 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]